Institutions / RA Capital Management, L.P.

RA Capital Management, L.P.

CIK 1346824 · Institutionalso an insider · as of Mar 31, 2026
Portfolio value
$9.44B
Positions
85
As of
Mar 31, 2026

Portfolio trend

Portfolio value

$9.44B-3.3%
$9.76B$9.60B$9.44BQ4 '25Q1 '26

Positions

85+19.7%
857871Q4 '25Q1 '26

Top holdings

Mar 31, 2026View all 85 →
CompanyClassValueShares% of portfolio
Ascendis Pharma A/S—$2.35B10,281,49624.9%
Vaxcyte, Inc.—$666.79M11,474,5997.1%
Rhythm Pharmaceuticals, Inc.—$579.81M6,666,8376.1%
Tyra Biosciences, Inc.—$467.21M12,198,6255.0%
Sionna Therapeutics, Inc.—$397.09M9,905,0454.2%
Edgewise Therapeutics, Inc.—$328.50M10,428,4373.5%
Newamsterdam Pharma Co NV—$305.70M9,550,1913.2%
Nuvalent, Inc.—$259.62M2,534,1452.8%
Dianthus Therapeutics, Inc.—$219.18M2,611,7332.3%
Mineralys Therapeutics IncMLYSCommon Stock$208.40M7,692,7502.2%
SpyGlass Pharma, Inc.SGPCommon Stock$207.83M8,021,1172.2%
Wave Life Sciences Ltd—$195.57M26,975,5052.1%
Septerna, Inc.SEPNCommon Stock$168.11M6,995,8581.8%
Disc Medicine, Inc.IRONCommon Stock$156.67M2,450,2211.7%
Janux Therapeutics, Inc.—$155.54M11,189,6931.6%
Biocryst Pharmaceuticals Inc—$150.67M15,827,1861.6%
Bicara Therapeutics Inc.—$144.32M7,255,9931.5%
Praxis Precision Medicines, Inc.—$120.43M373,7871.3%
Gh Research PLC—$107.93M7,676,6971.1%
Zai Lab Limited—$107.35M5,707,2621.1%
Taysha Gene Therapies, Inc.TSHACommon Stock$105.29M23,555,6481.1%
Vor Biopharma Inc.—$96.43M5,404,9981.0%
Geron Corp—$95.02M63,771,3661.0%
ARS Pharmaceuticals, Inc.—$87.21M10,860,9770.9%
Sarepta Therapeutics, Inc.—$84.92M3,902,5960.9%

Activity

Mar 31, 2026View full history →
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.
DateActionCompanyValueShares ΔPosition afterImpact
Q1 2026
as of
Exit171757206$-743.41M-3.4M
-100.00%
—
high
Q1 2026
as of
ExitAvidity Biosciences, Inc.$-623.28M-8.6M
-100.00%
—
high
Q1 2026
as of
NewSGP
SpyGlass Pharma, Inc.
Common Stock
$207.83M+8.0M
8,021,117
2.20% of portfolio
high
Q1 2026
as of
NewZai Lab Limited$107.35M+5.7M
5,707,262
1.14% of portfolio
high
Q1 2026
as of
NewSarepta Therapeutics, Inc.$84.92M+3.9M
3,902,596
0.90% of portfolio
high
Q1 2026
as of
AddDianthus Therapeutics, Inc.$83.92M+1.0M
+62.05%
2,611,733
2.32% of portfolio
high
Q1 2026
as of
ExitArcellx, Inc.$-82.62M-1.3M
-100.00%
—
high
Q1 2026
as of
ExitBLTE
Belite Bio, Inc
ADR
$-69.18M-432K
-100.00%
—
high
Q1 2026
as of
AddNuvalent, Inc.$67.01M+654K
+34.79%
2,534,145
2.75% of portfolio
high
Q1 2026
as of
AddY95308105$63.60M+8.8M
+48.19%
26,975,505
2.07% of portfolio
high

Insider transactions

Also files Forms 3 / 4 / 5
DateActionCompanyValueShares ΔPosition afterImpact
Jan 7, 2026OtherCDTX
Cidara Therapeutics, Inc.
Common Stock
$1.03B-4.7M
-100.00%
0
0.00% of shares
low
Jun 11, 2026BuyPBLS
Parabilis Medicines, Inc.
Voting Common Stock
$394.57M+19.7M
+300.89%
26,285,093
21.56% of shares
high
May 11, 2026BuyARTV
Artiva Biotherapeutics, Inc.
Common Stock
$75.00M+6.5M
+74.89%
15,203,995
31.10% of shares
high
Feb 9, 2026BuySGP
SpyGlass Pharma, Inc.
Common Stock
$55.07M+3.4M
+136.34%
5,966,439
17.84% of shares
high
May 4, 2026BuyCOAG
Hemab Therapeutics Holdings, Inc.
Common Stock
$45.74M+2.5M
+70.44%
6,149,096
13.16% of shares
high
Mar 26, 2026BuyWVE
Wave Life Sciences Ltd.
Ordinary Shares
$30.02M+5.0M
+27.22%
23,157,567
11.75% of shares
high
Jun 11, 2026BuyPBLS
Parabilis Medicines, Inc.
Voting Common Stock
$29.21M+1.5M
+122.94%
2,648,278
2.17% of shares
high
Mar 16, 2026GrantABOS
Acumen Pharmaceuticals, Inc.
Common Stock
$20.00M+6.1M
+46.47%
19,103,785
26.42% of shares
low
Mar 27, 2026BuyWVE
Wave Life Sciences Ltd.
Ordinary Shares
$16.05M+2.5M
+10.62%
26,004,414
13.20% of shares
high
Apr 6, 2026SellVOR
Vor Biopharma Inc.
Common Stock
$8.88M-538K
-10.45%
4,607,244
7.79% of shares
medium